secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066952
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Q1 net loss $23.9M; advances TERN-701 CML and TERN-601 obesity trials
---------------------------------------------------------------------------

- Net loss $23.9M ($0.26 EPS) vs $22.4M a year ago; R&D flat at $18.7M, G&A up to $8.7M.
- Cash, equivalents and marketable securities $334.3M at March 31, 2025; runway into 2028.
- Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 (CML); 6-month MMR data expected Q4 2025.
- Phase 2 FALCON trial of TERN-601 (obesity) enrolling; top-line 12-week weight loss data due Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017025066952/0000950170-25-066952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017025066952/tern-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer